Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARCTNASDAQ:ARDXNASDAQ:AUPHNASDAQ:GPCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$10.57+3.8%$13.73$8.04▼$45.00$286.66M3.41457,537 shs612,195 shsARDXArdelyx$4.64+1.5%$5.20$4.02▼$9.33$1.11B0.814.38 million shs4.80 million shsAUPHAurinia Pharmaceuticals$7.75+0.3%$8.00$4.71▼$10.67$1.06B1.21.35 million shs734,679 shsGPCRStructure Therapeutics$18.90-0.3%$20.74$13.22▼$62.74$1.08B-1.35874,475 shs884,831 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics+4.95%+11.99%-27.70%-38.64%-66.55%ARDXArdelyx+2.47%+2.70%-16.45%-18.68%-35.27%AUPHAurinia Pharmaceuticals+4.32%+1.84%-5.27%+2.38%+51.57%GPCRStructure Therapeutics+19.18%+32.42%-9.98%-25.33%-51.81%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARCTArcturus Therapeutics3.0217 of 5 stars4.60.00.00.02.42.51.3ARDXArdelyx4.2159 of 5 stars4.51.00.04.42.02.50.6AUPHAurinia Pharmaceuticals2.7061 of 5 stars3.51.00.00.03.70.81.9GPCRStructure Therapeutics2.5622 of 5 stars3.52.00.00.03.91.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARCTArcturus Therapeutics 3.13Buy$59.20460.08% UpsideARDXArdelyx 3.00Buy$10.61128.69% UpsideAUPHAurinia Pharmaceuticals 3.00Buy$11.5048.39% UpsideGPCRStructure Therapeutics 3.00Buy$81.29330.08% UpsideCurrent Analyst Ratings BreakdownLatest ARCT, ARDX, GPCR, and AUPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2025ARCTArcturus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.003/12/2025ARDXArdelyxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold3/10/2025ARCTArcturus TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$48.003/10/2025ARCTArcturus TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$74.00 ➝ $68.003/7/2025ARCTArcturus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$63.00 ➝ $60.003/7/2025ARCTArcturus TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/7/2025ARCTArcturus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$58.00 ➝ $50.003/7/2025ARDXArdelyxScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$15.003/7/2025ARDXArdelyxLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$11.003/4/2025ARDXArdelyxCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/4/2025ARDXArdelyxBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.00(Data available from 4/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARCTArcturus Therapeutics$138.39M2.07N/AN/A$10.42 per share1.01ARDXArdelyx$333.62M3.32N/AN/A$0.73 per share6.36AUPHAurinia Pharmaceuticals$235.13M4.53N/AN/A$2.63 per share2.95GPCRStructure TherapeuticsN/AN/AN/AN/A$9.77 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARCTArcturus Therapeutics-$29.73M-$3.01N/AN/AN/A-36.39%-22.39%-14.81%5/6/2025 (Estimated)ARDXArdelyx-$39.14M-$0.16N/A14.97N/A-11.73%-24.87%-10.51%5/1/2025 (Estimated)AUPHAurinia Pharmaceuticals-$78.02M$0.05N/A13.84N/A-10.23%-4.41%-3.07%5/1/2025 (Estimated)GPCRStructure Therapeutics-$89.62M-$0.79N/AN/AN/AN/A-16.37%-15.68%5/8/2025 (Estimated)Latest ARCT, ARDX, GPCR, and AUPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025GPCRStructure Therapeutics-$0.24N/AN/AN/AN/AN/A5/1/2025Q1 2025ARDXArdelyx-$0.10N/AN/AN/A$79.40 millionN/A5/1/2025Q1 2025AUPHAurinia Pharmaceuticals$0.09N/AN/AN/A$61.06 millionN/A3/6/2025Q4 2024ARCTArcturus Therapeutics-$0.33-$1.11-$0.78-$1.11$44.64 million$22.77 million2/27/2025Q4 2024GPCRStructure Therapeutics-$0.23-$0.22+$0.01-$0.22N/AN/A2/20/2025Q4 2024ARDXArdelyx$0.02$0.02N/A$0.02$111.16 million$116.13 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARCTArcturus Therapeutics$0.716.76%N/AN/A N/AARDXArdelyxN/AN/AN/AN/AN/AAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/AGPCRStructure TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARCTArcturus TherapeuticsN/A4.764.76ARDXArdelyx0.874.584.31AUPHAurinia Pharmaceuticals0.175.605.11GPCRStructure TherapeuticsN/A27.6327.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARCTArcturus Therapeutics94.54%ARDXArdelyx58.92%AUPHAurinia Pharmaceuticals36.83%GPCRStructure Therapeutics91.78%Insider OwnershipCompanyInsider OwnershipARCTArcturus Therapeutics15.30%ARDXArdelyx5.90%AUPHAurinia Pharmaceuticals4.30%GPCRStructure Therapeutics9.43%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARCTArcturus Therapeutics18027.12 million22.94 millionOptionableARDXArdelyx90238.36 million222.88 millionOptionableAUPHAurinia Pharmaceuticals300137.34 million137.02 millionOptionableGPCRStructure Therapeutics13657.34 million51.86 millionOptionableARCT, ARDX, GPCR, and AUPH HeadlinesRecent News About These CompaniesNVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study SetbackApril 15 at 11:00 AM | zacks.comWall Street Sees Pfizer's Weight-Loss Pill Exit As A Win For 2 Smaller Biotech Firms: Retail Turns BullishApril 15 at 6:34 AM | msn.comFmr LLC Sells 49,698 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)April 15 at 4:50 AM | marketbeat.comJPMorgan says Pfizer news ‘mostly a positive’ for Structure, VikingApril 14 at 8:30 PM | markets.businessinsider.comSmaller obesity drugmakers jump after Pfizer scraps weight-loss pillApril 14 at 8:30 PM | markets.businessinsider.comStructure Therapeutics shares rise on Pfizer’s obesity drug exitApril 14 at 3:29 PM | in.investing.comWhat's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?April 14 at 10:49 AM | benzinga.comStructure Therapeutics Inc. (NASDAQ:GPCR) Shares Purchased by Trexquant Investment LPApril 12 at 4:42 AM | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Hits New 12-Month Low - Time to Sell?April 11, 2025 | marketbeat.comStructure Therapeutics Inc. (NASDAQ:GPCR) Shares Sold by Federated Hermes Inc.April 10, 2025 | marketbeat.com35,319 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Purchased by ADAR1 Capital Management LLCApril 9, 2025 | marketbeat.comFranklin Resources Inc. Increases Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR)April 8, 2025 | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Shares Up 7.5% - What's Next?April 6, 2025 | marketbeat.comStructure Therapeutics Inc. (NASDAQ:GPCR) Shares Sold by Cinctive Capital Management LPApril 6, 2025 | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Stock Price Up 7.5% - Here's WhyApril 4, 2025 | marketbeat.comWellington Management Group LLP Has $211.15 Million Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR)April 4, 2025 | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Hits New 52-Week Low - What's Next?April 4, 2025 | marketbeat.comAmerican Century Companies Inc. Purchases 67,325 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)April 2, 2025 | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Trading Down 7.6% - What's Next?April 1, 2025 | marketbeat.comWhy Structure Therapeutics Inc.’s (GPCR) Stock Is Down 12.27%April 1, 2025 | aaii.comNEOS Investment Management LLC Has $1.20 Million Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR)March 31, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARCT, ARDX, GPCR, and AUPH Company DescriptionsArcturus Therapeutics NASDAQ:ARCT$10.57 +0.39 (+3.83%) Closing price 04:00 PM EasternExtended Trading$10.86 +0.29 (+2.74%) As of 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Ardelyx NASDAQ:ARDX$4.64 +0.07 (+1.53%) Closing price 04:00 PM EasternExtended Trading$4.60 -0.04 (-0.97%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Aurinia Pharmaceuticals NASDAQ:AUPH$7.75 +0.02 (+0.26%) Closing price 04:00 PM EasternExtended Trading$7.72 -0.03 (-0.39%) As of 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Structure Therapeutics NASDAQ:GPCR$18.90 -0.05 (-0.26%) Closing price 04:00 PM EasternExtended Trading$18.88 -0.02 (-0.11%) As of 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Stock is a Buy as Cyberthreat Environment Expands Congress! Who Traded What During the Tariff-Induced Meltdown Beware of BigBear.ai: Insiders Are Selling—Should You? NATO Deal Sparks 4% Jump in Palantir Stock—What’s Next? Microsoft: A Blend of Growth and Value Amid Tariff Concerns Why NVIDIA Stock Could Soar Despite Wall Street Downgrades Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold Don’t Fear, New Highs for Fastenal Will Soon Be Here Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
